IMF Opens March ‘Resilience’ Campaign for Myeloma Action Month
With an emphasis on the ability of patients and caregivers to adapt to challenges, the International Myeloma Foundation (IMF) is seeking to raise awareness…
News
Video: Bionews’ Social Media Campaign Highlights #WhatMakesMeRare
In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them…
FDA Approves Sarclisa Combo to Treat Advanced Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc), in combination with Pomalyst (pomalidomide) and dexamethasone,…
Loss of Specific Gene May Help Drive Myeloma Progression, Study Finds
One of the most common genomic defects in multiple myeloma patients is the loss of one copy of chromosome 13, and researchers now suggest that…
CLR 131 Helps Heavily Treated Multiple Myeloma Patients, Phase 2 Data Show
Cellectar Biosciences’ lead candidate CLR 131 safely and effectively prevents disease progression or reduces tumors in people with hard-to-treat multiple myeloma, according…
New CAR T-cell Therapy Shows Early Promise Against Multiple Myeloma in Lab Study
A new CAR T-cell therapy  for people with multiple myeloma has been successfully created and tested in…
Xpovio May Soon Be Available in Israel and Palestinian Authority, Karyopharm Says
Xpovio (selinexor), a treatment for advanced multiple myeloma, may soon be available in Israel and the Palestinian Authority through Promedico, under an exclusive…
Darzalex Combo Leads to Durable Responses in Patients With Advanced Multiple Myeloma, Follow-up Data Show
Janssen‘s Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and dexamethasone continues to lead to strong and durable responses, and…
Kleo’s KP1237 Therapy Soon Will Enter Clinical Testing, Following FDA’s Grant of New Drug Status
KP1237, an experimental therapy by Kleo Pharmaceutical that harnesses the body’s natural antibodies to fight cancers, will soon enter clinical testing for…
Phase 1/2 Trial of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma to Open Soon
A clinical trial is soon to begin testing Precision BioSciences‘s new CAR T-cell therapy candidate, PBCAR269A, in people with relapsed or refractory multiple myeloma.
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL